肿瘤浸润淋巴细胞在小细胞肺癌中的研究进展

小细胞肺癌（small cell lung cancer，SCLC）是一种预后极差的肺癌亚型，虽前期对放化疗敏感，但多数患者会在短期内因肿瘤复发、转移而死亡。探寻有效的、能指导预后及预测疗效的生物标志，以达到SCLC患者治疗的个体化和最优化是肿瘤研究的热门领域之一。目前有大量文献报道肿瘤浸润淋巴细胞（tumor-infiltrating lymphocytes，TILs）与较多类型癌种的（包括非小细胞肺癌、乳腺癌、结直肠癌、黑色素瘤等）预后及预测免疫治疗疗效的关系，本文将肿瘤浸润淋巴细胞在SCLC预后及疗效预测方面的作用作一综述。 

Role of tumor-infiltrating lymphocytes in small cell lung cancer

Small cell lung cancer (SCLC) is a subtype of lung cancer with poor prognosis. Although it is sensitive to radiotherapy and chemotherapy in the early stages, most patients die from tumor recurrence and metastasis in a short period of time. Lots of studies are aimed at investigating prognostic biomarkers and optimize the efficacy of drugs through individualization in patients with SCLC. There are many reports on the association between tumor-infiltrating lymphocytes (TILs) and prognosis of the tumor (including non-SCLC, breast cancer, colorectal cancer, and melanoma) and efficacy of immunotherapy. We review the role of TILs in the prognosis of SCLC and efficacy of drugs.